Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WXSH0493
- Development stage
- Phase 2
- Lead developer
- Lianyungang Kanion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
WXSH0493 is an investigational small molecule URAT1 inhibitor developed by Jiangsu Kanion Pharmaceutical for the management of hyperuricemia and gout. It targets the Solute Carrier Family 22 Member 12 (URAT1) transporter located on the apical membrane of proximal renal tubule cells. By inhibiting URAT1-mediated reabsorption of uric acid, WXSH0493 enhances uricosuric activity, leading to a reduction in serum uric acid levels. The compound is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetics in healthy volunteers and patients with hyperuricemia.
02
Targets
URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on WXSH0493.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WXSH0493.